Otherwise, it would have been perfectly conceivable to introduce an additional selection step to select clones based on their SARS-CoV-1 RBD binding in order to retain only clones with the desired cross-reactivity. The vast majority of our selected clones incorporate a subset of mutations consisting of S57G, T103V Ravuconazole and V104W substitutions. SARS-CoV-2 Introduction The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the current COVID-19 pandemic, which has had devastating consequences in many countries. To date, vaccination of populations appears to be the most effective approach to control the magnitude of the epidemic and to effectively protect the health of individuals. In high-risk infected patients, passive immunization by infusion of monoclonal antibodies constitutes a very interesting and complementary approach to vaccination. Indeed, several studies exhibited that early administration of monoclonal antibodies blocks entry of the virus in human cells by targeting the viral Spike protein and prevents progression to severe forms of the disease in patients. 1C3 Since early 2020, numerous studies have been dedicated to the development of monoclonal antibodies targeting the Spike protein and more particularly its receptor-binding domain name (RBD). 4 Multiple SARS-CoV-2 antibodies described in the literature bind the receptor-binding motif (RBM) of the Spike protein, i.e., the conversation site between the RBD domain name and ACE2. These monoclonal antibodies often exhibit excellent affinities, very good ability to neutralize the SARS-CoV-2 virus, and a protective effect EBY100 and their expression was induced. To finely compare the RBD binding of clones harboring mutations with VHH72, we introduced a small percentage (typically 5C10%) of cells expressing the parental clone along with intracellular enhanced green fluorescent protein (eGFP), using another plasmid (pSWG VHH72 eGFP). In that manner, parental clones pre-identified by their fluorescence signal corresponding to the eGFP expression (in black) can be readily identified during fluorescence-activated cell sorting (FACS) analysis to precisely define adequate sorting gates (Physique 1c). Upon induction and incubation with biotinylated RBD SARS-CoV-2 antigen, cells displaying variants with strong surface expression levels and augmented RBD binding relative to the parental clone were sorted (in red, Figure 1c). Overall, these sorted populations correspond to a relatively low percentage of cells expressing the VHH construct (5.5% and 11% in libraries L1 and L2, CD114 respectively), most mutants having similar or impaired RBD binding levels. Open in a separate window Physique 1. Deep mutational scanning probing VHH-72 binding to the RBD domain name from SARS-CoV2 Spike protein. (a) Two DNA libraries of VHH72 harbouring a single mutation (each corresponding to regions encompassing amino acids 1C59 and 60C125 of the nanobody) were transformed into yeast using gap repair recombination. (b) General theory of functional screening by yeast surface display. Cells are incubated with biotinylated RBD antigen and labelled with secondary reporters before FACS analysis to determine VHH expression and antigen binding. (c) Bivariate flow cytometry analysis of libraries L1 and L2 of yeast cells expressing VHH72 variants on their surface. Cells were double-labelled with biotinylated antigen/StreptavidinCPE (RBD SARS-CoV2 binding) and anti-HA tag antibody coupled to APC (VHH expression). Cells Ravuconazole corresponding to clones of the DMS libraries are represented in blue. Libraries were spiked with 10% of clonal cells expressing parental Ravuconazole VHH72 along with eGFP protein (represented in black) to discriminate cells with increased antigen binding levels. Selected cells (in red) were sorted and sequenced with illumina deep sequencing. Alt Text: Deep mutational scanning probing VHH-72 binding to the RBD domain name from SARS-CoV2 Spike protein. (a) Scheme illustrating the generation of DMS libraries, their cloning in plasmid and transfection of yeast cells. (b) Scheme representing yeast cells each expressing a mutated VHH72 nanobody. (c) Cytometry dot-plot figures obtained from the analysis of yeast expressing DMS libraries of VHH72. For each library, plasmid DNA was sequenced for both sorted and unsorted cells to evaluate the respective frequency of clones in these populations. For each Ravuconazole position and every substitution, enrichment ratios were calculated and represented as a functionality.